Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial

Derek Alderson; David Cunningham; Matthew Nankivell; Jane M. Blazeby; S. Michael Griffin; Adrian Crellin; Heike I. Grabsch; Rupert Langer; Susan Pritchard; Alicia Okines; Richard Krysztopik; Fareeda Coxon; Joyce Thompson; Stephen Falk; Clare Robb; Sally Stenning; Ruth E. Langley

doi:10.1016/S1470-2045(17)30447-3

Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial

Derek Alderson, David Cunningham^*, Matthew Nankivell, Jane M. Blazeby, S. Michael Griffin, Adrian Crellin, Heike I. Grabsch, Rupert Langer, Susan Pritchard, Alicia Okines, Richard Krysztopik, Fareeda Coxon, Joyce Thompson, Stephen Falk, Clare Robb, Sally Stenning, Ruth E. Langley

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	1249-1260
Number of pages	12
Journal	Lancet oncology
Volume	18
Issue number	9
DOIs	https://doi.org/10.1016/S1470-2045(17)30447-3
Publication status	Published - Sep 2017

Keywords

SQUAMOUS-CELL CARCINOMA
QUALITY-OF-LIFE
RESECTABLE GASTROESOPHAGEAL ADENOCARCINOMA
III TRIAL
PERIOPERATIVE CHEMOTHERAPY
PREOPERATIVE CHEMORADIOTHERAPY
JUNCTIONAL CANCER
TUMOR-REGRESSION
CLINICAL-TRIAL
SURGERY

Cite this

Alderson, D., Cunningham, D., Nankivell, M., Blazeby, J. M., Griffin, S. M., Crellin, A., Grabsch, H. I., Langer, R., Pritchard, S., Okines, A., Krysztopik, R., Coxon, F., Thompson, J., Falk, S., Robb, C., Stenning, S., & Langley, R. E. (2017). Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial. Lancet oncology, 18(9), 1249-1260. https://doi.org/10.1016/S1470-2045(17)30447-3

Alderson, Derek ; Cunningham, David ; Nankivell, Matthew ; Blazeby, Jane M. ; Griffin, S. Michael ; Crellin, Adrian ; Grabsch, Heike I. ; Langer, Rupert ; Pritchard, Susan ; Okines, Alicia ; Krysztopik, Richard ; Coxon, Fareeda ; Thompson, Joyce ; Falk, Stephen ; Robb, Clare ; Stenning, Sally ; Langley, Ruth E. / Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05) : an open-label, randomised phase 3 trial. In: Lancet oncology. 2017 ; Vol. 18, No. 9. pp. 1249-1260.

@article{f770e868cbab4b7d834966b35065517b,

title = "Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial",

keywords = "SQUAMOUS-CELL CARCINOMA, QUALITY-OF-LIFE, RESECTABLE GASTROESOPHAGEAL ADENOCARCINOMA, III TRIAL, PERIOPERATIVE CHEMOTHERAPY, PREOPERATIVE CHEMORADIOTHERAPY, JUNCTIONAL CANCER, TUMOR-REGRESSION, CLINICAL-TRIAL, SURGERY",

author = "Derek Alderson and David Cunningham and Matthew Nankivell and Blazeby, {Jane M.} and Griffin, {S. Michael} and Adrian Crellin and Grabsch, {Heike I.} and Rupert Langer and Susan Pritchard and Alicia Okines and Richard Krysztopik and Fareeda Coxon and Joyce Thompson and Stephen Falk and Clare Robb and Sally Stenning and Langley, {Ruth E.}",

year = "2017",

month = sep

doi = "10.1016/S1470-2045(17)30447-3",

language = "English",

volume = "18",

pages = "1249--1260",

journal = "Lancet oncology",

issn = "1470-2045",

publisher = "Elsevier Science",

number = "9",

}

Alderson, D, Cunningham, D, Nankivell, M, Blazeby, JM, Griffin, SM, Crellin, A, Grabsch, HI, Langer, R, Pritchard, S, Okines, A, Krysztopik, R, Coxon, F, Thompson, J, Falk, S, Robb, C, Stenning, S & Langley, RE 2017, 'Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial', Lancet oncology, vol. 18, no. 9, pp. 1249-1260. https://doi.org/10.1016/S1470-2045(17)30447-3

Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05) : an open-label, randomised phase 3 trial. / Alderson, Derek; Cunningham, David; Nankivell, Matthew; Blazeby, Jane M.; Griffin, S. Michael; Crellin, Adrian; Grabsch, Heike I.; Langer, Rupert; Pritchard, Susan; Okines, Alicia; Krysztopik, Richard; Coxon, Fareeda; Thompson, Joyce; Falk, Stephen; Robb, Clare; Stenning, Sally; Langley, Ruth E.

In: Lancet oncology, Vol. 18, No. 9, 09.2017, p. 1249-1260.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05)

T2 - an open-label, randomised phase 3 trial

AU - Alderson, Derek

AU - Cunningham, David

AU - Nankivell, Matthew

AU - Blazeby, Jane M.

AU - Griffin, S. Michael

AU - Crellin, Adrian

AU - Grabsch, Heike I.

AU - Langer, Rupert

AU - Pritchard, Susan

AU - Okines, Alicia

AU - Krysztopik, Richard

AU - Coxon, Fareeda

AU - Thompson, Joyce

AU - Falk, Stephen

AU - Robb, Clare

AU - Stenning, Sally

AU - Langley, Ruth E.

PY - 2017/9

Y1 - 2017/9

KW - SQUAMOUS-CELL CARCINOMA

KW - QUALITY-OF-LIFE

KW - RESECTABLE GASTROESOPHAGEAL ADENOCARCINOMA

KW - III TRIAL

KW - PERIOPERATIVE CHEMOTHERAPY

KW - PREOPERATIVE CHEMORADIOTHERAPY

KW - JUNCTIONAL CANCER

KW - TUMOR-REGRESSION

KW - CLINICAL-TRIAL

KW - SURGERY

U2 - 10.1016/S1470-2045(17)30447-3

DO - 10.1016/S1470-2045(17)30447-3

M3 - Article

VL - 18

SP - 1249

EP - 1260

JO - Lancet oncology

JF - Lancet oncology

SN - 1470-2045

IS - 9

ER -

Alderson D, Cunningham D, Nankivell M, Blazeby JM, Griffin SM, Crellin A et al. Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial. Lancet oncology. 2017 Sep;18(9):1249-1260. https://doi.org/10.1016/S1470-2045(17)30447-3

Access to Document

10.1016/S1470-2045(17)30447-3